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Background: We sought to determine whether a combination of an ACE inhibitor and the nutriceutical alpha-lipoic acid (ALA) regulates endothelial 
function and markers of inflammation in obese diabetic patients with Stage I hypertension.
Methods: 40 obese diabetic patients with Stage I hypertension that met the ATP III criteria for the metabolic syndrome were treated in a crossover 
fashion and in a double blinded manner to quinapril (40 mg/day) for 8 weeks or quinapril + ALA (600 mg/day) for 8 weeks. We measured 24 hour 
collection of urinary albumin and serum markers of adiponectin and leptin. We measured endothelial dependent flow mediated dilation in these 
patients (FMD).
Results: There was a change of metabolic parameters in both study groups after 8 weeks of therapy. In comparison to baseline, 24 hour urinary 
albumin decreased by 27 percent in the quinapril group (p=0.011 vs baseline) and 48 percent in the quinapril+ALA group (p<0.005 vs baseline 
and quinapril group). Levels of serum adiponectin increased by 17 percent (p<0.05 vs baseline) and serum leptin decreased by 19 percent in the 
quinapril group (p<0.05 vs baseline). Furthermore, these findings were augmented in the quinapril+ALA group; there was an increase in serum 
adiponectin levels by 33 percent (p<0.005 vs baseline and placebo) and a reduction of serum leptin levels by 40 percent (p<0.005 vs baseline and 
placebo). Also, in comparison to baseline, the FMD was increased by 22 percent in the quinapril group (p=0.055 vs baseline) and by 40 percent in 
the quinapril+ALA group (p<0.005 vs baseline; p=0.021 vs quinapril).
Conclusions: In diabetics with hypertension, quinapril improves endothelial function and has a favorable effect on biomarkers of obesity. 
Moreover, this effect is strongly potentiated with a combination of ALA and quinapril. These results may attenuate progression of pathophysiology 
seen in the metabolic syndrome.
